Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Carbon Chain Length Modulates MDA-MB-231 Breast Cancer Cell Killing Mechanisms by Mitochondrially Targeted Aryl-Urea Fatty Acids.

Murray M, Roseblade A, Chen Y, Bourget K, Rawling T.

ChemMedChem. 2020 Jan 17;15(2):247-255. doi: 10.1002/cmdc.201900577. Epub 2020 Jan 9.

PMID:
31773850
2.

Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib.

Murray M, Gillani TB, Rawling T, Nair PC.

AAPS J. 2019 Oct 21;21(6):107. doi: 10.1208/s12248-019-0374-2.

PMID:
31637538
3.

Identification of an allosteric binding site on the human glycine transporter, GlyT2, for bioactive lipid analgesics.

Mostyn SN, Wilson KA, Schumann-Gillett A, Frangos ZJ, Shimmon S, Rawling T, Ryan RM, O'Mara ML, Vandenberg RJ.

Elife. 2019 Oct 17;8. pii: e47150. doi: 10.7554/eLife.47150.

4.

l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.

Billings JL, Gordon SL, Rawling T, Doble PA, Bush AI, Adlard PA, Finkelstein DI, Hare DJ.

J Neurochem. 2019 Jul;150(1):88-106. doi: 10.1111/jnc.14676. Epub 2019 Mar 28.

PMID:
30716176
5.

Development of an N-Acyl Amino Acid That Selectively Inhibits the Glycine Transporter 2 To Produce Analgesia in a Rat Model of Chronic Pain.

Mostyn SN, Rawling T, Mohammadi S, Shimmon S, Frangos ZJ, Sarker S, Yousuf A, Vetter I, Ryan RM, Christie MJ, Vandenberg RJ.

J Med Chem. 2019 Mar 14;62(5):2466-2484. doi: 10.1021/acs.jmedchem.8b01775. Epub 2019 Feb 20.

6.

Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4.

Ghassabian S, Gillani TB, Rawling T, Crettol S, Nair PC, Murray M.

AAPS J. 2019 Jan 9;21(2):15. doi: 10.1208/s12248-018-0262-1.

PMID:
30627802
7.

Aryl-urea fatty acids that activate the p38 MAP kinase and down-regulate multiple cyclins decrease the viability of MDA-MB-231 breast cancer cells.

Al-Zubaidi Y, Pazderka C, Koolaji N, Rahman MK, Choucair H, Umashankar B, Bourget K, Chen Y, Rawling T, Murray M.

Eur J Pharm Sci. 2019 Mar 1;129:87-98. doi: 10.1016/j.ejps.2018.12.015. Epub 2018 Dec 29.

PMID:
30597206
8.

Nanoemulsion-Enabled Oral Delivery of Novel Anticancer ω-3 Fatty Acid Derivatives.

Garrastazu Pereira G, Rawling T, Pozzoli M, Pazderka C, Chen Y, Dunstan CR, Murray M, Sonvico F.

Nanomaterials (Basel). 2018 Oct 13;8(10). pii: E825. doi: 10.3390/nano8100825.

9.

Omega-3 Polyunsaturated Fatty Acid Derived Lipid Mediators and Their Application in Drug Discovery.

Pazderka CW, Oliver B, Murray M, Rawling T.

Curr Med Chem. 2018 Sep 26. doi: 10.2174/0929867325666180927100120. [Epub ahead of print]

PMID:
30259807
10.

Antiproliferative activities of alkaloid-like compounds.

Xu X, Rawling T, Roseblade A, Bishop R, Ung AT.

Medchemcomm. 2017 Oct 25;8(11):2105-2114. doi: 10.1039/c7md00435d. eCollection 2017 Nov 1.

11.

Carboxylate Analogues of Aryl-Urea-Substituted Fatty Acids That Target the Mitochondria in MDA-MB-231 Breast Cancer Cells to Promote Cell Death.

Koolaji N, Rawling T, Bourget K, Murray M.

ChemMedChem. 2018 May 23;13(10):1036-1043. doi: 10.1002/cmdc.201800018. Epub 2018 Apr 23.

PMID:
29603659
12.

Activity of novel lipid glycine transporter inhibitors on synaptic signalling in the dorsal horn of the spinal cord.

Winters BL, Rawling T, Vandenberg RJ, Christie MJ, Bhola RF, Imlach WL.

Br J Pharmacol. 2018 Jun;175(12):2337-2347. doi: 10.1111/bph.14189. Epub 2018 Apr 14.

13.

Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.

Murray M, Gillani TB, Ghassabian S, Edwards RJ, Rawling T.

Eur J Pharm Sci. 2018 Mar 1;114:55-63. doi: 10.1016/j.ejps.2017.12.003. Epub 2017 Dec 7.

PMID:
29223619
14.

A Novel Arylurea Fatty Acid That Targets the Mitochondrion and Depletes Cardiolipin To Promote Killing of Breast Cancer Cells.

Rawling T, Choucair H, Koolaji N, Bourget K, Allison SE, Chen YJ, Dunstan CR, Murray M.

J Med Chem. 2017 Oct 26;60(20):8661-8666. doi: 10.1021/acs.jmedchem.7b00701. Epub 2017 Oct 5.

PMID:
28921987
15.

A novel synthetic analogue of ω-3 17,18-epoxyeicosatetraenoic acid activates TNF receptor-1/ASK1/JNK signaling to promote apoptosis in human breast cancer cells.

Dyari HRE, Rawling T, Chen Y, Sudarmana W, Bourget K, Dwyer JM, Allison SE, Murray M.

FASEB J. 2017 Dec;31(12):5246-5257. doi: 10.1096/fj.201700033R. Epub 2017 Aug 10.

PMID:
28798154
16.

Synthesis and Characterization of Novel Acyl-Glycine Inhibitors of GlyT2.

Mostyn SN, Carland JE, Shimmon S, Ryan RM, Rawling T, Vandenberg RJ.

ACS Chem Neurosci. 2017 Sep 20;8(9):1949-1959. doi: 10.1021/acschemneuro.7b00105. Epub 2017 Jun 15.

PMID:
28574249
17.

Anti-tumor activities of lipids and lipid analogues and their development as potential anticancer drugs.

Murray M, Hraiki A, Bebawy M, Pazderka C, Rawling T.

Pharmacol Ther. 2015 Jun;150:109-28. doi: 10.1016/j.pharmthera.2015.01.008. Epub 2015 Jan 17. Review.

PMID:
25603423
18.

Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity.

Gillani TB, Rawling T, Murray M.

Chem Res Toxicol. 2015 Jan 20;28(1):92-102. doi: 10.1021/tx500373g. Epub 2014 Dec 23.

PMID:
25489883
19.

Selective inhibition of human solute carrier transporters by multikinase inhibitors.

Johnston RA, Rawling T, Chan T, Zhou F, Murray M.

Drug Metab Dispos. 2014 Nov;42(11):1851-7. doi: 10.1124/dmd.114.059097. Epub 2014 Aug 27.

PMID:
25165131
20.

Synthetic ω-3 epoxyfatty acids as antiproliferative and pro-apoptotic agents in human breast cancer cells.

Dyari HR, Rawling T, Bourget K, Murray M.

J Med Chem. 2014 Sep 11;57(17):7459-64. doi: 10.1021/jm501083y. Epub 2014 Aug 29.

PMID:
25144895

Supplemental Content

Loading ...
Support Center